ANXA1 has been shown to reduce BBB permeability in sepsis-associated encephalopathy (138), while in neonatal HIE, depletion of ANXA1 is associated with temporal loss of BBB integrity and is suggested as a therapeutic target (139). Here, ANXA1 is linked to perinatal asphyxia.